Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin Effects on Dopamine in First Episode Psychosis
NCT07252752Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of Generex Oral-lyn in schizophrenia (3 arms), sponsored by Medical University of Vienna. Primary endpoints: [11C]-(+)-PHNO BPND values and Hippocampal glucose and glutamate concentrations. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07252752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252752.